Switching of Hormone Therapies in Breast Cancer Women.

Author: FerraciniAmanda Canato, JuliatoCassia Raquel Teatin, MazzolaPriscila Gava, MedeirosLuana Moreira de, SouzaCinthia Madeira de, StahlschmidtRebeca

Paper Details 
Original Abstract of the Article :
OBJECTIVE:  The objective of the present study was to analyze the reasons that led to hormone therapies (HTs) regimen changes in women with breast cancer. METHODS:  This was a retrospective cross-sectional study from a single-institution Brazilian cancer center with patient records diagnosed with b...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183841/

データ提供:米国国立医学図書館(NLM)

Switching Hormone Therapies in Breast Cancer: Understanding the Reasons

Hormone therapies (HTs) play a crucial role in the management of breast cancer. This study investigates the reasons for switching HT regimens in women with breast cancer. The researchers analyzed data from a single-institution Brazilian cancer center, examining the factors that led to changes in HT treatment plans. The study provides valuable insights into the clinical considerations and patient characteristics that contribute to HT switching, informing clinical decision-making and patient care.

Navigating Hormone Therapy: Understanding the Landscape

The study reveals that disease progression, including cancer recurrence, metastasis, or increased tumor size, is the most common reason for switching HT regimens. Side effects are also a significant factor, particularly in women with comorbidities. The researchers identify specific patient characteristics associated with HT switching, such as age, menopausal status, and ethnicity. This research provides valuable insights into the clinical considerations and patient characteristics that drive HT switching decisions in breast cancer management.

Empowering Patients: Sharing the Journey

This research underscores the importance of open communication and shared decision-making in breast cancer management. Healthcare professionals should discuss the potential benefits and risks of different HT options with patients, ensuring they understand the reasons for any treatment changes. Patients should actively participate in their care, understanding their condition, treatment options, and the importance of regular monitoring. This collaborative approach can empower patients, improve treatment adherence, and ultimately lead to better outcomes.

Dr. Camel's Conclusion

Navigating the treatment of breast cancer is like traversing a vast desert with multiple pathways. This research helps us understand the reasons for switching hormone therapies, providing a map to guide patients and healthcare professionals through this challenging journey.

Date :
  1. Date Completed 2021-10-14
  2. Date Revised 2023-07-28
Further Info :

Pubmed ID

33465792

DOI: Digital Object Identifier

PMC10183841

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.